Effects of dapagliflozin on prevention of major clinical events and recovery in patients with respiratory failure because of COVID‐19: Design and rationale for the DARE‐19 study

AIMS: Coronavirus disease 2019 (COVID‐19) is caused by a novel severe acute respiratory syndrome coronavirus 2. It can lead to multiorgan failure, including respiratory and cardiovascular decompensation, and kidney injury, with significant associated morbidity and mortality, particularly in patients...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Diabetes Obes Metab
Hlavní autoři: Kosiborod, Mikhail, Berwanger, Otavio, Koch, Gary G., Martinez, Felipe, Mukhtar, Omar, Verma, Subodh, Chopra, Vijay, Javaheri, Ali, Ambery, Philip, Gasparyan, Samvel B., Buenconsejo, Joan, Sjöström, C. David, Langkilde, Anna Maria, Oscarsson, Jan, Esterline, Russell
Médium: Artigo
Jazyk:Inglês
Vydáno: Blackwell Publishing Ltd 2021
Témata:
Clinical Trial Design
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8049025/
https://ncbi.nlm.nih.gov/pubmed/33319454
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.14296
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky